0.635
price down icon2.25%   -0.0146
after-market アフターアワーズ: .65 0.015 +2.36%
loading
前日終値:
$0.6496
開ける:
$0.64
24時間の取引高:
1.30M
Relative Volume:
1.43
時価総額:
$80.13M
収益:
$140.46M
当期純損益:
$-146.34M
株価収益率:
-0.4811
EPS:
-1.32
ネットキャッシュフロー:
$-117.73M
1週間 パフォーマンス:
-9.29%
1か月 パフォーマンス:
-18.06%
6か月 パフォーマンス:
-33.03%
1年 パフォーマンス:
-16.25%
1日の値動き範囲:
Value
$0.6251
$0.6589
1週間の範囲:
Value
$0.6251
$0.7178
52週間の値動き範囲:
Value
$0.6251
$1.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
名前
Karyopharm Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
617-658-0600
Name
住所
85 WELLS AVENUE, NEWTON, MA
Name
職員
325
Name
Twitter
@Karyopharm
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
KPTI's Discussions on Twitter

KPTI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
0.635 80.13M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-01-19 開始されました Piper Sandler Overweight
2022-11-04 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-09 アップグレード JP Morgan Underweight → Neutral
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-08-06 ダウングレード JP Morgan Overweight → Neutral
2021-08-06 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-08-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-07-02 開始されました Morgan Stanley Overweight
2020-03-04 開始されました Barclays Overweight
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-07-23 アップグレード JP Morgan Neutral → Overweight
2019-07-05 繰り返されました H.C. Wainwright Buy
2019-07-05 繰り返されました Robert W. Baird Outperform
2019-03-01 ダウングレード JP Morgan Overweight → Neutral
2019-02-28 繰り返されました BofA/Merrill Underperform
2019-02-27 ダウングレード BofA/Merrill Neutral → Underperform
2019-01-03 アップグレード BofA/Merrill Underperform → Neutral
2018-12-03 開始されました B. Riley FBR Buy
2018-11-09 アップグレード Wedbush Neutral → Outperform
2018-05-24 ダウングレード Wedbush Outperform → Neutral
2018-04-02 再開されました Leerink Partners Outperform
2017-11-15 再開されました H.C. Wainwright Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2016-09-08 繰り返されました H.C. Wainwright Buy
2016-08-30 アップグレード Jefferies Hold → Buy
2016-08-18 開始されました H.C. Wainwright Buy
2016-06-28 開始されました Robert W. Baird Outperform
すべてを表示

Karyopharm Therapeutics Inc (KPTI) 最新ニュース

pulisher
Dec 21, 2024

Fmr LLC Buys 76,510 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World

Dec 21, 2024
pulisher
Dec 18, 2024

KPTI stock touches 52-week low at $0.65 amid market challenges By Investing.com - Investing.com South Africa

Dec 18, 2024
pulisher
Dec 18, 2024

KPTI stock touches 52-week low at $0.65 amid market challenges - Investing.com Canada

Dec 18, 2024
pulisher
Dec 16, 2024

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online

Dec 16, 2024
pulisher
Dec 16, 2024

Karyopharm Therapeutics Inc.'s SWOT analysis: oncology firm's stock faces pivotal trials - Investing.com

Dec 16, 2024
pulisher
Dec 12, 2024

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - The Eastern Progress Online

Dec 12, 2024
pulisher
Dec 10, 2024

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - Kilgore News Herald

Dec 10, 2024
pulisher
Dec 09, 2024

Karyopharm Appoints Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - citybiz

Dec 09, 2024
pulisher
Dec 06, 2024

Karyopharm CEO Richard Paulson sells $2,932 in stock By Investing.com - Investing.com Nigeria

Dec 06, 2024
pulisher
Dec 05, 2024

Karyopharm CEO Richard Paulson sells $2,932 in stock - Investing.com

Dec 05, 2024
pulisher
Dec 04, 2024

Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World

Dec 04, 2024
pulisher
Dec 04, 2024

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - Defense World

Dec 04, 2024
pulisher
Dec 03, 2024

Karyopharm Engages with FDA on Cancer Trial Plans - TipRanks

Dec 03, 2024
pulisher
Dec 03, 2024

Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics

Dec 03, 2024
pulisher
Dec 03, 2024

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Growth in Short Interest - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

Karyopharm reports inducement grants under Nasdaq listing rule - TipRanks

Dec 02, 2024
pulisher
Dec 02, 2024

Karyopharm Therapeutics Awards 4,800 RSUs to New Employees in Retention Plan - StockTitan

Dec 02, 2024
pulisher
Nov 30, 2024

Karyopharm Therapeutics (STU:25K) Operating Cash Flow per S - GuruFocus.com

Nov 30, 2024
pulisher
Nov 26, 2024

KPTI (Karyopharm Therapeutics) Market Cap : $109.8 Mil (As of Nov. 26, 2024) - GuruFocus.com

Nov 26, 2024
pulisher
Nov 26, 2024

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Lowered by StockNews.com - Defense World

Nov 26, 2024
pulisher
Nov 25, 2024

Karyopharm Therapeutics' SWOT analysis: oncology stock faces pivotal trials - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 - GlobeNewswire Inc.

Nov 25, 2024
pulisher
Nov 25, 2024

Karyopharm Therapeutics to Present at Piper Sandler Healthcare Conference | KPTI Stock News - StockTitan

Nov 25, 2024
pulisher
Nov 21, 2024

Karyopharm appoints new chief accounting officer By Investing.com - Investing.com Canada

Nov 21, 2024
pulisher
Nov 21, 2024

Karyopharm gains after changes to late-stage trial - MSN

Nov 21, 2024
pulisher
Nov 21, 2024

Karyopharm appoints new chief accounting officer - Investing.com India

Nov 21, 2024
pulisher
Nov 21, 2024

Karyopharm Therapeutics Appoints Kristin Abate Chief Accounting Officer - citybiz

Nov 21, 2024
pulisher
Nov 20, 2024

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer - Citizentribune

Nov 20, 2024
pulisher
Nov 20, 2024

Karyopharm Therapeutics Appoints New Chief Accounting Officer - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

Karyopharm appoints Kristin Abate as Chief Accounting Officer - TipRanks

Nov 20, 2024
pulisher
Nov 18, 2024

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition - PR Newswire

Nov 18, 2024
pulisher
Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition of Karyop - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com Nigeria

Nov 14, 2024
pulisher
Nov 14, 2024

Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

GSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat

Nov 14, 2024

Karyopharm Therapeutics Inc (KPTI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Karyopharm Therapeutics Inc (KPTI) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Paulson Richard A.
President and CEO
Nov 05 '24
Sale
0.91
3,675
3,346
1,131,932
Paulson Richard A.
President and CEO
Oct 04 '24
Sale
0.88
3,607
3,172
1,135,607
Mano Michael
SVP, General Counsel&Secretary
Sep 04 '24
Sale
0.72
3,971
2,866
273,881
Paulson Richard A.
President and CEO
Sep 04 '24
Sale
0.72
3,667
2,647
1,139,214
Mason Michael
EVP, CFO & Treasurer
Sep 04 '24
Sale
0.72
7,050
5,089
391,054
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Sep 04 '24
Sale
0.72
5,356
3,866
404,051
Paulson Richard A.
President and CEO
Aug 06 '24
Sale
0.93
3,608
3,355
1,142,881
Poulton Stuart
EVP, Chief Development Officer
Jul 30 '24
Sale
1.06
2,883
3,056
326,628
Paulson Richard A.
President and CEO
Jul 05 '24
Sale
0.85
3,616
3,077
1,146,489
PAKIANATHAN DEEPIKA
Director
Jun 05 '24
Sale
0.96
468,044
448,480
3,385
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):